Treatment > Carmustine

N Engl J Med 2000 Nov 9;343(19):1350-4. (Clinical Study, Abstract)
Erratum in: N Engl J Med 2000 Dec 7;343(23):1740
Comment in: N Engl J Med. 2000 Nov 9;343(19):1408-9. N Engl J Med. 2001 Mar 1;344(9):686; discussion 687-8. 
N Engl J Med. 2001 Mar 1;344(9):686; discussion 687-8. N Engl J Med. 2001 Mar 1;344(9):687; discussion 687-8.

Abstract

Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents

Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, Baylin SB, Herman JG

Division of Cancer Biology, Johns Hopkins Oncology Center, Baltimore, MD 21231, USA

Background. The DNA-repair enzyme O6-methylguanine-DNA methyltransferase (MGMT) inhibits the killing of tumor cells by alkylating agents.
MGMT activity is controlled by a promoter; methylation of the promoter silences the gene in cancer, and the cells no longer produce MGMT.
We examined gliomas to determine whether methylation of the MGMT promoter is related to the responsiveness of the tumor to alkylating agents.

Methods. We analyzed the MGMT promoter in tumor DNA by a methylation-specific polymerase-chain-reaction assay. The gliomas were obtained from patients who had been treated with carmustine (1,3-bis(2-chloroethyl)-1-nitrosourea, or BCNU).
The molecular data were correlated with the clinical outcome.

Results. The MGMT promoter was methylated in gliomas from 19 of 47 patients (40 percent).
This finding was associated with regression of the tumor and prolonged overall and disease-free survival.
It was an independent and stronger prognostic factor than age, stage, tumor grade, or performance status.

Conclusions. Methylation of the MGMT promoter in gliomas is a useful predictor of the responsiveness of the tumors to alkylating agents.

PMID: 11070098 [PubMed - indexed for MEDLINE]